Blog

Blog

In vivo CAR-T Insights Series (3) — Antibody Selection in Ab-LNP Process

Linkedin

Release Time：

2025-12-03 15:58

 

In Vivo CAR-T has opened a new frontier in cell therapy by generating functional CAR-T cells directly inside the patient’s body. Among the different delivery strategies, antibody-conjugated lipid nanoparticles (Ab-LNPs) stand out for their ability to target T cells with precision.

🔎 Why antibody selection matters

The antibody is the “address label” of the nanoparticle. Choosing the right one determines whether the therapeutic cargo reaches the right T cell subset, thereby impacting both efficacy and safety.

📌 Common T cell surface markers for targeting

  • CD3 – Pan-T cell activation and expansion
  • CD4 – Helper T cell targeting for immune modulation
  • CD5 – Broad T cell and subset-specific targeting
  • CD7 – Highly expressed in T cells, used in clinical LNP research
  • CD8 – Cytotoxic T cell targeting for tumor clearance

⚙️ Antibody screening criteria

  • Affinity & specificity – ensure strong binding to the target marker without cross-reactivity
  • Immunogenicity profile – minimize adverse immune responses during repeated dosing
  • Engineering flexibility – Fc mutations, humanization, or single-chain formats for stable LNP attachment
  • Manufacturability – scalable and reproducible antibody production for clinical use

🔧 Conjugation strategies in practice

  • Direct conjugation – straightforward coupling of antibody to LNP surface; efficient but can face challenges with orientation and stability
  • Linker-optimized conjugation – introduces chemical linkers that control antibody orientation, improve stability, and enhance repeat dosing potential

📈 Clinical relevance

Recent preclinical studies show that CD5- and CD7-directed Ab-LNPs achieve efficient in vivo CAR-T generation, highlighting how antibody choice directly impacts therapeutic outcomes. This underlines the importance of rational antibody selection as the foundation of successful in vivo CAR-T translation.

💡 Key takeaway

The antibody is more than a targeting element — it’s a design lever that shapes the delivery efficiency, safety, and clinical applicability of Ab-LNP platforms.

Levostar’s in vivo CAR-T solutions

From mRNA plasmid design to LNP formulation, Levostar provides complete solutions for in vivo CAR-T research.

🌟 Levostar’s technical advantages in antibody conjugation

  • Flexible antibody selection – compatible with diverse T cell targets (CD3, CD5, CD7, CD8…)
  • Multiple antibody formats – full-length antibodies, Fab fragments, scFv for tailored applications
  • Custom antibody synthesis – de novo antibody synthesis from sequence, followed by LNP conjugation

 Let’s accelerate the future of cell therapy — directly inside the body. 

Prev

In vivo CAR-T Insights Series (4) — The Role of mRNA in In vivo CAR-T

In vivo CAR-T Insights Series (2) — Delivery Strategies Landscape

Next